Cancer News and Research

Latest Cancer News and Research

Mentally ill smokers also benefit from treatment, says research paper

People with mental illnesses such as depression and anxiety are the heaviest smokers in the country, but their doctors are afraid to ask them to quit. They assume that if their patients try to quit smoking, their mental disorders will get worse.

9 Sep 2009

American Asthma Foundation awards $750,000 for asthma research

Dr. Serpil Erzurum, one of the nation's leading experts in asthma, has been awarded $750,000 by the American Asthma Foundation (AAF). Dr. Erzurum will collaborate with experts in nuclear medicine and physics to develop an innovative way for clinicians to observe changes in the lungs of patients during an asthma attack.

9 Sep 2009

Chemgenex completes NDA submission for its omacetaxine mepesuccinate to the FDA

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

9 Sep 2009

American International Pathology Laboratories provides jobs to Walter Reed AFIP pathologists

American International Pathology Laboratories (AIPL), a division of Bostwick Laboratories, opens its doors today, providing positions to more than 40 civilian pathologists and staff formerly of the Armed Forces Institute of Pathology at Walter Reed Army Medical Center. The 150-year-old Institute will cease operations when Walter Reed closes under the Federal Base Realignment and Closure program.

9 Sep 2009

Cepheid's Flu Panel test to provide 45-minute identification of Flu A infection

Cepheid (Nasdaq: CPHD) today announced the accelerated development of a Flu A (Influenza Virus) Panel test for use on the GeneXpert((R)) System. The test will be designed to provide 45-minute identification of Flu A infection, with specific presumptive identification of seasonal H1, seasonal H3, and H1N1 novel strain types.

9 Sep 2009

Protox Therapeutics to present TRIUMPH clinical study update

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that Dr. Fahar Merchant, President & CEO of Protox Therapeutics, will present at the 11th Annual Rodman & Renshaw Healthcare Conference.

9 Sep 2009

New television program to raise awareness about cardiovascular diseases in women

Research shows that 80 percent of cardiac events in women could be prevented if women make the right choices for their hearts, involving diet, exercise and abstinence from smoking.

9 Sep 2009

CEO Cancer Gold Standard accreditation for ASCO

The American Society of Clinical Oncology (ASCO) has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

9 Sep 2009

IntrinsiQ to discuss clinical oncology treatment guidelines

IntrinsiQ president Jeff Forringer will discuss clinical oncology treatment guidelines – and what drives variations from the standard-of-care – at the 6th Annual ICORE/Magellan Oncology Summit this Friday in New York.

9 Sep 2009

AOLS to initiate clinical study for testing the efficacy of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that it has initiated a study to confirm the efficacy of AEOL 10150 as a countermeasure to nuclear and radiological exposure in non-human primates.

9 Sep 2009

International summit on the H1N1 influenza pandemic and critical business preparedness

The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota is convening an international summit on the H1N1 influenza pandemic and critical business preparedness.

9 Sep 2009

Dana-Farber Cancer Institute reaches milestone: $1 billion raised in campaign

Dana-Farber Cancer Institute today announced it has reached its $1 billion Mission Possible: The Dana-Farber Campaign to Conquer Cancer fundraising goal one year early. The first hospital in New England to set and reach a $1 billion campaign goal, Dana-Farber will continue to raise funds for campaign priorities until Sept. 30, 2010, when the campaign was scheduled to end.

9 Sep 2009

INSPIRE Phase I/IIa study data to be presented at ICAAC

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its INSPIRE Phase I/IIa study of HIV-infected patients with low CD4 T cell counts treated with a three injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), will be presented during an oral late breaker session at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held September 12-15, 2009, in San Francisco, CA.

9 Sep 2009

Physicians to educate Congress on the importance of reducing viral hepatitis

The National Viral Hepatitis Roundtable (NVHR) is hosting a briefing, "The Experts' Perspective: Gaps and Strategies in the Hepatitis Crisis." "Leading hepatitis physicians, one of whom is a Congressman, will be on the hill today to educate Congress on the importance of developing a strategy to reduce the significant morbidity and mortality from end-stage liver disease and liver cancer caused by chronic hepatitis B and chronic hepatitis C in the United States," said Martha Saly, Director of NVHR.

9 Sep 2009

GENova Biotherapeutics discusses its anti-cancer drug development strategy

GENova Biotherapeutics, Inc., ("GENova"), today released important information about its anti-cancer drug development strategy and its unique niche in the drug development industry.

9 Sep 2009

Congress urged to include injury prevention in health care reform

A group of 18 research centers, professional organizations and advocacy groups have joined together to urge Congress to include injury prevention in health care reform. Each day, 475 Americans die from injuries related to motor vehicle crashes, assaults, fires and other trauma. This results in 170,000 deaths every year, more than twice that from diabetes and more than four times that of breast cancer.

9 Sep 2009

PDL BioPharma announces revenue guidance for the third quarter ended September 30, 2009

PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the third quarter ended September 30, 2009 of approximately $71 million, as compared with $69 million for the third quarter of 2008. Royalty revenues are based on second quarter product sales by PDL's licensees and include $1.6 million for Synagis(R), which is marketed by MedImmune.

9 Sep 2009

International Institute of Biomedical Sciences and Technology established for a global research initiative

Upstate Medical University in Syracuse, New York, the Technion-Israel Institute of Technology in Haifa, Israel, and National Cheng Kung University in Tainan City, Taiwan, have announced the creation of the International Institute of Biomedical Sciences and Technology that will facilitate the collaboration of research across three continents and accelerate the development of novel bioengineering, diagnostic and biomedical products for the treatment and cure of disease, officials said today.

9 Sep 2009

Bayer submits an IND for its MN-IC antibody-drug conjugate to the FDA

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Bayer Schering Pharma AG, Germany. The milestone was triggered by Bayer’s submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for MN-IC, an ADC for solid tumors.

9 Sep 2009

Patient enrollment completed in Phase II clinical trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients.

9 Sep 2009